[HTML] plos.org

[HTML][HTML] Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy

I Pérez-Valero, A González-Baeza, M Estébanez… - PLoS …, 2013 - journals.plos.org
Background In patients who remain virologically suppressed in plasma with triple-drug ART
a switch to protease inhibitor monotherapy maintains high rates of suppression; however it is …
被引用次数：30 相关文章

[引用][C] Neurocognitive Impairment in Patients Treated with Protease Inhibitor Monotherapy or Triple Drug Antiretroviral Therapy

I Pérez-Valero, A González-Baeza, M Estébanez… - PLoS …, 2013 - ui.adsabs.harvard.edu
Neurocognitive Impairment in Patients Treated with Protease Inhibitor Monotherapy or Triple
Drug Antiretroviral Therapy - NASA/ADS Now on home page ads icon ads Enable full ADS view …
[HTML] nih.gov

[HTML][HTML] Neurocognitive Impairment in Patients Treated with Protease Inhibitor Monotherapy or Triple Drug Antiretroviral Therapy

I Pérez-Valero, A González-Baeza, M Estébanez… - PLoS ONE, 2013 - ncbi.nlm.nih.gov
Background In patients who remain virologically suppressed in plasma with triple-drug ART
a switch to protease inhibitor monotherapy maintains high rates of suppression; however it is …

Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy.

I Pérez-Valero, A González-Baeza, M Estébanez… - Plos one, 2013 - europepmc.org
Background In patients who remain virologically suppressed in plasma with triple-drug ART
a switch to protease inhibitor monotherapy maintains high rates of suppression; however it is …

Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy.

I Pérez-Valero, A González-Baeza, M Estébanez… - 2013 - cabidigitallibrary.org
Background: In patients who remain virologically suppressed in plasma with triple-drug ART
a switch to protease inhibitor monotherapy maintains high rates of suppression; however it is …

Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy

I Pérez-Valero, A González-Baeza… - PloS …, 2013 - pubmed.ncbi.nlm.nih.gov
Background In patients who remain virologically suppressed in plasma with triple-drug ART
a switch to protease inhibitor monotherapy maintains high rates of suppression; however it is …
[PDF] semanticscholar.org

[PDF][PDF] Neurocognitive Impairment in Patients Treated with Protease

I Pérez-Valero, A González-Baeza, M Estébanez… - 2013 - pdfs.semanticscholar.org
Background: In patients who remain virologically suppressed in plasma with triple-drug ART
a switch to protease inhibitor monotherapy maintains high rates of suppression; however it is …
[PDF] researchgate.net

[PDF][PDF] Neurocognitive Impairment in Patients Treated with Protease

I Pérez-Valero, A González-Baeza, M Estébanez… - 2013 - researchgate.net
Background: In patients who remain virologically suppressed in plasma with triple-drug ART
a switch to protease inhibitor monotherapy maintains high rates of suppression; however it is …
[PDF] scienceopen.com

[PDF][PDF] Neurocognitive Impairment in Patients Treated with Protease

I Pérez-Valero, A González-Baeza, M Estébanez… - 2013 - scienceopen.com
Background: In patients who remain virologically suppressed in plasma with triple-drug ART
a switch to protease inhibitor monotherapy maintains high rates of suppression; however it is …

Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy

I Pérez-Valero, A González-Baeza, M Estébanez… - 2013 - lareferencia.info
BACKGROUND: In patients who remain virologically suppressed in plasma with triple-drug
ART a switch to protease inhibitor monotherapy maintains high rates of suppression; …